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INTRODUCTION
The prevalence of asthma and allergic disease has increased 
substantially during the past three or four decades.
1,2 Although 
it has been stabilized or has decreased in most high-prevalence 
countries (such as English-speaking countries) since 2000, its 
prevalence is still increasing in population-dense countries in 
Africa, Latin America and parts of Asia.
3,4 Overall, the global 
burden of asthma is continuing to rise.
The hygiene/old friends hypothesis was proposed to explain 
the rise in the prevalence of asthma/allergy.
5 This hypothesis 
states that an increase in the prevalence of asthma/allergy is re-
lated to diminished exposure to infections and certain relative-
ly harmless environmental organisms or components that the 
immune system has learned to tolerate.
6 Many investigators, in-
cluding our group,
7-12 have shown that Mycobacterium bovis 
bacille Calmette-Guérin (BCG) and other mycobacterial infec-
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tions suppress airway hyperresponsiveness (AHR) and eosino-
philic inflammation, likely through a T-helper 1 (Th1) or regu-
latory T cell (Treg) response. Furthermore, we found that BCG 
and M. tuberculosis culture supernatants also suppressed asth-
matic reactions.
13
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Purpose:  Live/killed mycobacteria and culture supernatants can suppress asthmatic reactions. This study investigated whether mycobacterial se-
cretory proteins have therapeutic effects on asthma.  Methods:  Mycobacterium bovis bacille Calmette-Guérin (BCG; 2×10
5 CFUs) and mycobacte-
rial secretory proteins (Ag85 complex, 38-kDa protein or MPB70; 4 or 20 μg) were administered intraperitoneally to female BALB/c mice with estab-
lished airway hyperresponsiveness. One week after treatment, the mice underwent a methacholine challenge test, and then inflammatory cell num-
bers in bronchoalveolar lavage fluid (BAL) and around bronchi (<500 μm), and cytokine levels in splenocyte supernatants, were assessed.  Results: 
BCG and all of the tested secretory proteins significantly improved airway sensitivity compared to baseline values (P<0.05). The secretory protein 
Ag85 complex significantly suppressed airway reactivity also (P<0.05), while 38-kDa protein significantly suppressed reactivity and maximal narrow-
ing (P<0.05). The number of eosinophils in BAL and around bronchi, and the goblet cell proportion, were also significantly reduced in mice in both 
the BCG and secretory protein groups compared to the asthma control group. IFN-γ/IL-5 ratios were significantly higher in mice treated with BCG, 4 
μg MPB70 or 4 μg 38-kDa protein than in asthma control mice (P<0.05), and were negatively associated with airway hyperresponsiveness, peribron-
chial eosinophil numbers and goblet cell proportion (all P<0.05). IL-17A was positively correlated with IL-5 (r=0.379, P<0.001), maximal airway nar-
rowing, peribronchial eosinophil numbers and goblet cell proportion (all P<0.05).  Conclusions:  Secretory proteins from BCG and M. tuberculosis 
and live BCG were effective against established asthma, their effects being accompanied by increased IFN-γ/IL-5 ratios. Thus, allergic asthma could 
be effectively treated with mycobacterial secretory proteins.
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The antigen 85 complex (Ag85) is a major constituent of the 
secreted proteins of M. tuberculosis and BCG that can induce 
interferon (IFN)-γ secretion from Th1 cells.
14 38-kDa protein is 
also actively secreted from M. tuberculosis
15 and stimulates IFN-γ 
secretion.
16 MPB70, another protein that induces IFN-γ produc-
tion, is a major secreted protein of BCG but is only secreted in 
small quantities from M. tuberculosis.
17 This study aimed to de-
termine which of the enriched secretory proteins of mycobac-
teria have therapeutic effects on asthma.
 
MATERIALS AND METHODS
Experimental animals
Specific pathogen-free, 6-week-old female BALB/c mice 
(Daehan BioLink, Eumsung, Korea) were fed standard mouse 
chow and given water ad libitum in an animal care room at 
Chonnam National University Medical School, Korea. Animal 
care and treatment followed the guidelines of the Chonnam 
National University Research Institute of Medical Sciences and 
the study was approved by the Chonnam National University 
Institutional Animal Care and Use Committees (CNU IACUC-
H-2009-9). Mice were divided into nine groups: one normal 
control group, one asthma control group, one live BCG-treated 
group (n=10 per group), and six mycobacterial secretory pro-
tein-treated groups (n=8 per group).
Study design
Mice were sensitized and provoked with ovalbumin (Grade V; 
Sigma-Aldrich, St. Louis, MO, USA), and those that developed 
AHR to methacholine (Sigma) were selected as the experimen-
tal animals, as described previously (Fig. 1).
18 AHR was defined 
as airway sensitivity >95% of the confidence interval of the non-
sensitized normal control group, and the asthma threshold was 
16.3 mg/mL. Mice with established AHR were treated intraper-
itoneally with live BCG or mycobacterial secretory proteins. One 
week after treatment, they underwent a second provocation test 
with ovalbumin, followed by a methacholine challenge test, 
and then were sacrificed so that inflammatory cell numbers in 
bronchoalveolar lavage (BAL) fluid and around bronchi (<500 
μm), and cytokine levels in the splenocyte culture supernatants, 
could be quantified.
Ovalbumin sensitization and provocation, and administration 
of mycobacterial proteins
Mice were sensitized through two intraperitoneal injections of 
200 μL phosphate-buffered saline (PBS; BioWhittaker
TM, MD, 
USA) containing 20 μg ovalbumin and 2.25 mg aluminum hy-
droxide (Imject Alum; Pierce Biotechnology, Rockford, IL, USA) 
2 weeks apart. One week after the second sensitization, the 
mice were provoked with 1% ovalbumin aerosol using an Ultra-
Neb ultrasonic nebulizer (DeVilbiss, Somerset, PA, USA) in an 
OCP3000 animal body plethysmograph (All Medicus, Anyang, 
Korea) for 30 minutes per day for three successive days. The 
normal control group was sensitized and provoked with PBS 
alone.
Pathogenic M. tuberculosis H37Rv (ATCC 27294) and M. bovis 
BCG (Tokyo 172 strain; Korean National Tuberculosis Associa-
tion, Seoul, Korea) were cultured at 37°C as surface pellicles on 
Sauton’s medium. After 6 weeks, the bacilli were removed by 
filtration through filter paper. The culture supernatants were se-
quentially sterilized using membrane filters (pore size 1.2 and 
0.2 μm) and concentrated by ultrafiltration (Amicon Cen-
triprep-10, Millipore, Billerica, MA, USA).
Ag85 (0.632 mg/mL) and 38-kDa protein (0.95 mg/mL) were 
purified from the culture supernatants of M. tuberculosis, as de-
scribed previously.
15,19,20 MPB70 protein (1.8 mg/mL) from BCG 
culture supernatants was purified by a two-step process: hy-
droxylapatite chromatography followed by anion-exchange 
chromatography. Briefly, a 50%-80% ammonium sulfate precip-
itate of BCG culture filtrate was dissolved and dialyzed against 
1 mM potassium phosphate buffer (PB, pH 7.0), loaded to a 
column of hydroxylapatite equilibrated with 1 mM PB, and 
eluted with 1 mM PB (because MPB70 was not retained on the 
column). Further purification was performed by anion-ex-
change chromatography using DEAE-Sepharose CL-6B. MPB70 
protein was eluted with 0 to 50 mM NaCl in 20 mM Tris-HCl 
(pH 8.0). The purified proteins were dialyzed against PBS, filter 
sterilized, and frozen at -80°C. Protein concentrations were de-
termined using a protein assay kit (Pierce) with bovine serum 
albumin as the standard.
To prepare a live bacterial stock, BCG was cultured at 36°C for 
3 weeks in a sealed 1:1 semisolid mixture of Middlebrook 7H10 
agar (Becton Dickinson, Cockeysville, MD, USA) and Middle-
brook 7H9 broth (Becton Dickinson) supplemented with 10% 
oleic acid-albumin-dextrose-catalase (Becton Dickinson). Col-
onies were counted before preparation of the inoculum. Live 
BCG (2×10
5 CFUs) or purified mycobacterial secretory proteins 
(4 or 20 μg) were administered intraperitoneally to mice with 
established AHR.
Fig. 1.  The time course of the experiment. OVA, ovalbumin; ip, intraperitoneal; 
BCG, bacille Calmette-Guérin; MBPT, methacholine bronchoprovocation test.
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Lung function tests
Airway responsiveness to methacholine was measured using 
the OCP3000 body plethysmograph, as described previously.
21 
Briefly, the animals inhaled PBS aerosol and then progressively 
doubled concentrations of methacholine (starting from 3.125 
mg/mL and increasing to 100 mg/mL at 24-hour after the final 
ovalbumin inhalation challenge). Aerosols were generated us-
ing an Ultra-Neb nebulizer, and 3 mL solution was aerosolized 
for 3 minutes. Enhanced pause (Penh) was used to represent air-
way resistance. The methacholine concentration required for a 
200% increase in Penh from the post-saline value (PC200), the max-
imal response to methacholine (Maximal Penh), and the slope of 
the methacholine dose-response curve (by linear regression) 
(DRS) were calculated as indices of airway sensitivity, excessive 
airway narrowing, and airway reactivity, respectively. As a three-
fold improvement in PC20 is considered significant in occupa-
tional asthma,
22 the fold increase in PC200 (i.e., ratio of second 
PC200 value to first PC200 value) was calculated to evaluate the 
degree of improvement after treatment.
Analysis of cells in BAL fluid and lung tissue
Forty-eight hours after the last ovalbumin provocation, the 
mice were sacrificed by intraperitoneal injection of 5 mg/kg 
thiopental sodium. BAL samples were taken, and total and dif-
ferential cell counts in the BAL fluid were determined, as de-
scribed previously.
21 Briefly, the lungs were lavaged with 3.6 mL 
cold 0.9% saline via the trachea. After counting total cells, cyto-
spin preparations (CF-120; Sakura Fine-Technical, Tokyo, Japan) 
were stained with Diff-Quick (International Reagents, Kobe, Ja-
pan). The percentage of each cell type was calculated from the 
average of 300 consecutive cells counted on each of two slides 
(magnification, ×400).
The left lung was fixed in 4% formalin and embedded in par-
affin for histopathological analysis. The embedded tissue was 
sectioned to a thickness of 4 μm and stained with hematoxylin-
eosin and periodic acid-Schiff. Small airways (circumference 
<500 μm) were selected
23 and numbers of eosinophils, lym-
phocytes, and neutrophils within the peribronchial area from 
the basement membrane to a depth of 100 μm were determined 
using a Nikon microscope using AnalySIS
® Pro image analysis 
software (Soft Imaging System GmbH, Münster, Germany) and 
expressed as number of cells/mm
2.
24 Goblet cell hyperplasia 
was evaluated according to a 5-point scoring system (0-4) as 
follows: 0, no goblet cells; 1, <25%; 2, 25%-50%; 3, 50%-75%; 
and 4, ≥75%.
25
Cytokine assays
Splenocyte culture and cytokine measurements were per-
formed as described previously.
21 Briefly, splenocytes were cul-
tured in RPMI 1640 medium (BioWhittaker, Walkersville, MD, 
USA) supplemented with 10% fetal bovine serum (Gibco BRL, 
Grand Island, NY, USA) and a 1% penicillin-streptomycin-am-
photericin B mixture (BioWhittaker), and were stimulated with 
2.5 μg/mL concanavalin A (Sigma) for 48 hours. IFN-γ, IL-5, and 
IL-17A concentrations in the supernatants of stimulated sple-
nocytes were determined using commercial enzyme-linked 
immunosorbent assay (ELISA) kits (BioLegend, Inc., San Diego, 
CA, USA). The sensitivities of the assays for IFN-γ, IL-5, and IL-
17A were 4, 8, and 7.8 pg/mL, respectively.
Statistical analysis
PC200 values were log10-transformed before analysis, and all 
data are expressed as the mean±SEM. The Kruskal-Wallis test 
and Mann-Whitney U test were used to determine the signifi-
cance of the intergroup differences, and the Wilcoxon signed-
rank test was used to determine the significance of the intra-
group differences. Associations between variables were exam-
ined using Spearman’s rank correlation coefficient. A P value of 
<0.05 was considered statistically significant.
RESULTS
Methacholine-AHR
The Penh values after PBS inhalation in the treatment groups 
were not significantly different than those in the asthma control 
group either before or after the treatment with live BCG or my-
cobacterial secretory proteins. In addition, the pre-treatment 
PC200, Maximal Penh, and DRS values in the treatment groups 
were not significantly different than those in the asthma control 
group (Table 1). However, treatment with BCG or mycobacteri-
al secretory proteins, but not PBS, significantly improved airway 
sensitivity (PC200). While the maximal Penh value was only signif-
icantly reduced in the 38-kDa protein-treated group, the DRS 
was significantly reduced in animals treated with BCG, 4 μg 
Ag85, or 4 μg 38-kDa protein. The fold increase in PC200 value af-
ter treatment (second PC200 value/first PC200 value) was signifi-
cantly higher in the BCG-treated group (1.44±0.09) than in the 
asthma control group (1.06±0.06) (P<0.01), and was also sig-
nificantly higher in all groups treated with mycobacterial secre-
tory proteins. The fold increases in PC200 value in the mycobac-
terial secretory protein-treated groups were not significantly 
different than those in the BCG group.
The PC200 value after treatment was significantly lower in the 
asthma control group than in the normal control group (Fig. 2). 
The PC200 values in all treatment groups were significantly high-
er than in the asthma control group. Similarly, the maximal Penh 
and DRS values were significantly higher in the asthma control 
group than in the normal control group. In addition, the values 
in the treatment groups, except for maximal Penh values in the 4 
μg MPB70 and 20 μg 38-kDa protein groups and for DRS values 
in the 20 μg MPB70 and 20 μg Ag85 groups, were significantly 
lower than those in the asthma control group. Compared to the 
normal control group, all treatment groups showed significant 
differences in PC200 and maximal Penh values. However, the DRS Treatment of Asthma With Mycobacterial Proteins
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values for the BCG, 4 μg Ag85, and 4 μg 38-kDa protein groups 
were not significantly different than those for the normal con-
trol group.
Cells in BAL fluid and lung tissue
The proportion of eosinophils in the BAL fluid was significant-
ly higher in the asthma control group than in the normal con-
trol group, and significantly lower in all treatment groups than 
in the asthma control group. However, the eosinophil propor-
tions in all of the treatment groups were significantly higher 
than that in the normal control group (data not shown). Simi-
larly, the number of eosinophils in the peribronchial tissue was 
significantly higher in the asthma control group than in the 
normal control group, and significantly lower in all treatment 
groups than in the asthma control group (Fig. 3). Numbers of 
Table 1.  Airway sensitivity (PC200), excessive airway narrowing (maximal Penh), and airway reactivity (DRS) in mice before and after treatment with BCG or mycobac-
terial secretory proteins
PC200 (geometric mean, mg/mL) Maximal Penh DRS
Before After Before After Before After
Normal control 73.5 71.8 351±22 349±32 52±3 51±6
Asthma control 7.9 8.5 1,090±138 1,628±417 206±33 226±38
BCG  9.9 26.0
† 977±132 695±61 155±21 81±11*
MPB70, 4 μg 8.1 21.9* 958±222 886±187 106±38 109±22
MPB70, 20 μg 7.7 20.2* 846±128 650±76 129±22 107±18
Ag85 complex, 4 μg 8.2 27.7* 842±77 672±313 148±15 75±10*
Ag85 complex, 20 μg 8.2 21.1* 765±64 818±81 127±18 106±16
38-kDa, 4 μg 8.0 30.9* 1,010±136 600±94* 174±25 66±8*
38-kDa, 20 μg 6.5 25.6* 822±143 816±156 135±33 83±12
Data are expressed as the mean±standard error.
PC200, concentration of methacholine required for a 200% increase in enhanced pause (Penh) index from baseline; DRS, dose-response slope; BCG, bacille Calmette-
Guérin.*P<0.05, 
†P<0.01 vs. pretreatment values.
Fig. 2.  PC200 was significantly higher in all treatment groups than in the asth-
ma control group. PC200: concentration of methacholine required for a 200% in-
crease in enhanced pause index from baseline. *P<0.05, 
†P<0.001 vs. the 
asthma control group.
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neutrophils/lymphocytes in all treatment groups were not sig-
nificantly different than those in the asthma control group. In 
addition, the proportion of goblet cells in the bronchial epithe-
lium was significantly higher in the asthma control group than 
in the normal control group, and all treatment groups showed a 
significantly lower proportion of goblet cells compared to the 
asthma control group (Fig. 3). However, peribronchial eosino-
phil numbers and goblet cell proportions were significantly 
higher in all treatment groups than in the normal control group.
Concentrations of cytokines in splenocyte culture supernatants
In the supernatants of concanavalin A-stimulated splenocytes, 
the IFN-γ level was significantly lower (499±58 vs. 860±97 pg/
mL, P<0.05) and the IL-5 level significantly higher (211±81 vs. 
90±10, P<0.001) in the asthma control group than in the nor-
mal control group, resulting in a significantly lower IFN-γ/IL-5 
in the asthma control group (2.8±0.5 vs. 9.8±1.1, P<0.001) 
(Fig. 4). The IFN-γ/IL-5 ratio was significantly higher in the 
groups treated with BCG (5.9±1.1, P<0.05), 4 μg MPB70 (5.6±
1.2, P<0.05), and 4 μg 38-kDa protein (5.0±0.8, P<0.05) com-
pared to the asthma control group. The IFN-γ/IL-5 ratio was 
significantly lower in the group treated with 4 μg Ag85 (3.2±0.4, 
P<0.05) than in the 4 μg MPB70 group. The IFN-γ/IL-5 ratios 
for all treatment groups were significantly lower than that for 
the normal control group. The IL-17A level was significantly 
higher in the asthma control group than in the normal control 
group (171.0±22.7 vs. 73.8±7.1 pg/mL, P<0.01). However, IL-
17A levels in all treatment groups, while significantly higher 
than that in the normal control group, were not significantly 
different than that in the asthma control group.
For all subjects, the IFN-γ/IL-5 ratios in the splenocyte culture 
supernatants were significantly associated with AHR, peribron-
chial eosinophil, and neutrophil numbers, and goblet cell hy-
perplasia (Table 2). IL-17A level showed a significant relation-
ship with maximal airway narrowing, peribronchial eosinophil 
numbers, and goblet cell hyperplasia, and was also significant-
ly correlated with IL-5 level (r=0.379, P<0.001).
DISCUSSION
Treatment with mycobacterial secretory proteins had thera-
peutic effects on AHR and eosinophilic airway inflammation in 
mice. These results are consistent with those of previous studies 
showing that mycobacteria such as BCG have suppressive ef-
fects on asthma.
7-9,11,13,21,26 However, whole BCG bacteria, even if 
heat-killed, could not be repeatedly administered to patients 
with asthma due to side effects.
27 The results of this study sug-
gest that mycobacterial secretory proteins such as Ag85, 38-kDa 
protein, and MPB70, which may have fewer side effects than 
whole bacteria, may be effective for the treatment of asthma as 
a result of suppression of AHR and eosinophilic airway inflam-
mation. In our previous study,
13 heat-killed preparations of BCG 
and M. tuberculosis did not effectively suppress airway sensitiv-
ity, while Shirtcliffe et al.
27 reported that heat-killed BCG had no 
therapeutic effect on patients with asthma. However, because 
both BCG and M. tuberculosis culture supernatants effectively 
suppressed asthmatic reactions in our previous study,
13 and be-
cause secretory components in culture supernatants effectively 
suppressed asthmatic reactions in the present study, it is antici-
pated that mycobacterial secretory proteins would be effective 
for treating human asthma as well.
The mycobacterial cell wall glycolipids lipoarabinomannan 
(LAM) and phosphatidylinositol mannan (PIM) can suppress 
airway eosinophilia through IL-10 production by T cells.
28 In 
addition, M. tuberculosis chaperonin 60.1 can also suppress air-
way eosinophilia and methacholine-AHR.
29 Mannose-capped 
LAM from M. bovis BCG Tokyo-172 enhances the differentiation 
of human peripheral blood naïve CD4 T cells into Th1 cells.
30 
Mannose-capped LAM
31 and chaperonin 60.1
29 from M. tuber-
culosis can suppress asthmatic reactions through Treg cell in-
duction. Thus, many mycobacterial cell wall components seem 
to have therapeutic effects on asthma through the above mech-
Table 2.  Correlation coefficients for cytokine levels in splenocyte culture su-
pernatants and markers of asthmatic airway reactions in mice treated with 
BCG or mycobacterial secretory proteins
IFN-γ/IL-5 IL-17A
PC200 (mg/mL) 0.288* -0.167
Maximal Penh (%) -0.367
† 0.257*
Dose-response slope -0.265* 0.015
Peribronchial eosinophil (/mm
2) -0.527
‡ 0.279*
Peribronchial neutrophil (/mm
2) -0.305
† 0.167
Goblet cell proportion (%) -0.273* 0.327
†
BCG, bacille Calmette-Guérin.
*P<0.05, 
†P<0.01, 
‡P<0.001.
Fig. 4.  IFN-γ/IL-5 ratios in splenocyte culture supernatants were higher in the 
BCG, 4 μg MPB70, and 4 μg 38-kDa protein groups than in the asthma control 
group. *P<0.05, 
†P<0.001 vs. the asthma control group.
I
F
N
-
γ
 
/
 
I
L
-
5
 
r
a
t
i
o
 
i
n
 
s
p
l
e
n
o
c
y
t
e
 
s
u
p
e
r
n
a
t
a
n
t
12
10
8
6
4
2
0
Normal
Asthma
BCG
MPB70 4 μg
MPB70 20 μg
Ag85 4 μg
Ag85 20 μg
38-kDa 4 μg
38-kDa 20 μg
†
*
*
*Treatment of Asthma With Mycobacterial Proteins
Allergy Asthma Immunol Res. 2012 July;4(4):214-221.  http://dx.doi.org/10.4168/aair.2012.4.4.214
AAIR 
219 http://e-aair.org
anisms. However, because heat-killed mycobacteria were inef-
fective against AHR in our previous study,
13 and because Major 
et al.
32 also showed that heat-killed BCG was less effective in 
suppressing airway eosinophilia than live BCG, these mycobac-
terial cell wall components seem to be heat-labile. Means et 
al.
33 showed that a cell-associated mycobacterial factor that was 
distinct from LAM and that mediated Toll-like receptor (TLR)4-
dependent activation was heat-sensitive, while a factor in the 
culture supernatant that activated cells in a TLR2-dependent 
manner was heat-stable. The mycobacterial secretory proteins 
in this study might be such heat-stable mycobacterial factors.
The Ag85 complex, which consists of secreted proteins from 
M. tuberculosis, is composed of Ag85A, Ag85B, and Ag85C, of 
which Ag85A and Ag85B induce a strong Th1-like response.
34 
Wu et al.
35 showed in 2009 that an Ag85B DNA vaccine sup-
pressed eosinophilic airway inflammation in a murine model 
of asthma, and Mori et al.
36 reported that Ag85B suppressed 
Th2 cytokine-mediated acute-phase atopic inflammatory reac-
tions by increasing Foxp3
+ Treg cell numbers in an atopic der-
matitis mouse model. Because 38-kDa protein
16 and MPB70
17 
induce IFN-γ production, they may also be effective for treating 
asthma. To the best of our knowledge this study is the first to 
prove it.
In a large epidemiological study, an increase in tuberculosis 
notification rates of 25 per 100,000 was associated with a 4.7% 
decrease in the prevalence of wheezing,
37 while BCG vaccina-
tion had only a weak protective effect against asthma.
38 There-
fore, secretory proteins from M. tuberculosis may have a strong 
therapeutic effect against asthma compared to BCG. In this 
study, 38-kDa protein and Ag85 of M. tuberculosis suppressed 
all three components of AHR (airway sensitivity, excessive air-
way narrowing, and airway reactivity), while MPB70 of BCG 
suppressed only airway sensitivity. Because M. tuberculosis in-
duces the production of four times more IFN-γ than does BCG,
39 
we speculated that secretory proteins of M. tuberculosis would 
induce the production of greater amounts of IFN-γ than do BCG 
proteins, but this was not the case. The IFN-γ/IL-5 ratio was 
higher in the MPB70-treated group than in the Ag85-treated 
group in this study. Hence, the superior effect of M. tuberculosis 
on AHRmay not primarily depend on IFN-γ but Treg cells. How-
ever, further studies are required to confirm this. In this study, 
the lower dose of 38-kDa protein and Ag85 from M. tuberculosis 
tested (4 μg) was more effective at suppressing AHR than the 
higher dose (20 μg), similar to the observation of Lin et al.,
18 who 
found that addition of high-dose dehydroepiandrosterone to 
BCG reduced the efficacy of BCG. Although the reason for this 
paradoxical response is not clear, a plausible explanation can 
be found in a report by Yoshida et al.,
40 who showed that ongo-
ing AHR following allergen challenge in IFN-γ-deficient mice 
was resolved by treatment with IFN-γ for 1 week, but aggravated 
by treatment for 4 weeks. Thus, the superfluous IFN-γ in mice 
treated with higher doses might not have a beneficial effect on 
asthma, but may instead be detrimental, even if it is transient, 
as brief Th1-related exacerbation of asthma may follow respira-
tory viral infection.
41 Further investigation is necessary to deter-
mine the proper doses of mycobacterial secretory proteins for 
effective treatment of asthma.
Although the changes in the IFN-γ/IL-5 ratio after treatment 
did not coincide well with the effects of mycobacterial compo-
nent treatment on AHR or airway cells, the ratios tended to be 
higher in the treatment groups than the asthma control group, 
and the IFN-γ/IL-5 ratio was significantly correlated with AHR, 
airway eosinophilia, and goblet cell proportion. These results 
are consistent with previous reports showing that mycobacte-
ria
7-11,21,26,42 and their components
29 produced suppressive ef-
fects by shifting the Th1/Th2 balance to Th1. Because Treg cells 
can suppress airway eosinophilia through suppression of both 
Th1 and Th2 cells by secreting IL-10 and transforming growth 
factor-β,
12 it is necessary to check these cytokine levels. Howev-
er, we were unable to do this because they were undetectable in 
a preliminary study. Meanwhile, IL-17A was significantly asso-
ciated with maximal airway narrowing and goblet cell propor-
tion in this study. IL-17 produced by Th17 cells was recently re-
ported to mediate neutrophilic airway inflammation and AHR.
43 
In contrast to this previous report,
43 IL-17A levels were associat-
ed with peribronchial infiltration of eosinophils, but not neu-
trophils, in the present study. IL-17A levels showed a significant 
relationship with IL-5 levels, corroborating a report by Bullens 
et al.,
44 who showed that IL-17 mRNA level was correlated with 
IL-5 mRNA level in sputum from patients with asthma. Thus, 
while its role in asthma is unclear, IL-17A seems unlikely to pro-
mote the therapeutic effects of mycobacterial secretory proteins.
Various mycobacterial lipoproteins are recognized by TLR2 in 
association with TLR1/TLR6 or by TLR4 on the surface of anti-
gen-presenting cells (APCs) and induce naïve T cells to differ-
entiate, mainly into Th1/Treg cells (immune polarization), with 
the help of IL-12 and IL-10 secreted from APCs.
45 Lipomannan, 
the precursor of LAM, is recognized by TLR2, ManLAMs by the 
mannose receptor or DC-SIGN, PIM by TLR2,
46,47 chaperonin 
60.1 by TLR4,
29 and 38-kDa glycolipoprotein by both TLR2 and 
TLR4. However, for Ag85, there is only one report showing that 
it does not stimulate TLR2 or TLR4,
48 and for MPB70, no pat-
tern recognition receptor has yet been identified. Therefore, 
further investigation in this area is necessary.
MPB70, a BCG secretory protein, was as effective as live BCG 
for the treatment of established asthma in this study. In our pre-
vious study,
21 among the various strains of BCG, the Tokyo 172 
strain, but not the Pasteur F1173P2, Tice, or Connaught strains, 
significantly suppressed AHR. Because MPB70 is present at 
high concentrations in Tokyo strain culture supernatants, but 
only in very small amounts in Pasteur, Tice, and Copenhagen 
strain culture supernatants,
49 the strain-dependency of the ef-
fects of BCG on asthma may be affected by differences in MPB70 
levels between the various strains.Han et al.
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Because cytokine levels in the splenocyte culture supernatants 
may not exactly reflect the local airway status, it would be better 
to measure cytokine levels directly in the airways. We tried for 
the first time to detect cytokine mRNAs in the lungs of mice by 
semi-quantitative RT-PCR, but the results were disappointingly 
not interpretable and we therefore did not present them in this 
study. We did not obtain any data on innate immunity because 
we have no experience with TRL studies. Further experiments 
on this are desirable in the future. Although Hamelmann et al.
50 
reported that an increase in Penh in response to inhaled metha-
choline is a valid indicator of AHR, AHR measurements must 
be validated using a more rigorous method.
In conclusion, mycobacterial secretory proteins were, like live 
BCG, effective for the treatment of established asthma, and in-
creased the IFN-γ/IL-5 ratio. Thus, allergic asthma can be effec-
tively treated with mycobacterial secretory proteins.
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